Appendix D. 
Clinton Administration NIH Guidelines for 
Embryonic Stem Cell Funding 
As printed in the Federal Register, August 25, 2000 ("National 
Institutes of Health Guidelines for Research Using Human 
Pluripotent Stem Cells," 65 Fed. Reg. 51,975, Aug. 25, 2000) 
The text of the final Guidelines follows. 
National Institutes of Health Guidelines for Research Using Human 
Pluripotent Stem Cells 
I. Scope of Guidelines 
These Guidelines apply to the expenditure of National Institutes of 
Health (NIH) funds for research using human pluripotent stem cells 
derived from human embryos (technically known as human 
embryonic stem cells) or human fetal tissue (technically knovvm as 
human embryonic germ cells). For purposes of these Guidelines, 
' ' human pluripotent stem cells" are cells that are self-replicating, are 
derived from human embryos or human fetal tissue, and are known to 
develop into cells and tissues of the three primary germ layers. 
Although human pluripotent stem cells may be derived from embryos 
or fetal tissue, such stem cells are not themselves embryos. NIH 
research funded under these Guidelines will involve human 
pluripotent stem cells derived: (1) From human fetal tissue; or (2) 
from human embryos that are the result of in vitro fertilization, are in 
excess of clinical need, and have not reached the stage at which the 
mesoderm is formed. 
In accordance with 42 Code of Federal Regulations (CFR) 52.4, 
these Guidelines prescribe the documentation and assurances that 
must accompany requests for NIH funding for research using human 
pluripotent stem cells from: (1) Awardees who want to use existing 
funds; (2) awardees requesting an administrative or competing 
supplement; and (3) applicants or intramural researchers submitting 
applications or proposals. NIH funds may be used to derive human 
pluripotent stem cells from fetal tissue. NIH funds may not be used to 
derive human pluripotent stem cells from human embryos. These 
189 
